Comments

Werewolf Therapeutics

HOWLNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$2.74
0.020.74%
At Close: -
$2.74
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Werewolf Therapeutics (HOWL) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$26.00
Lowest Price Target1
$8.30
Consensus Price Target1
$13.90

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Werewolf Therapeutics (NASDAQ:HOWL) Stock, Analyst Ratings, Price Targets, Forecasts

Werewolf Therapeutics Inc has a consensus price target of $13.9 based on the ratings of 7 analysts. The high is $26 issued by B of A Securities on September 10, 2021. The low is $8.3 issued by EF Hutton on May 25, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., JMP Securities, and HC Wainwright & Co. on July 2, 2024, June 26, 2024, and June 26, 2024, respectively. With an average price target of $14 between HC Wainwright & Co., JMP Securities, and HC Wainwright & Co., there's an implied 410.95% upside for Werewolf Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
0
0
0
0
Apr
0
0
0
0
May
0
0
0
0
Jun
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
JMP Securities
Wedbush
EF Hutton
B of A Securities

1calculated from analyst ratings

Analyst Ratings for Werewolf Therapeutics

Buy NowGet Alert
07/02/2024Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
$15 → $15ReiteratesBuy → BuyGet Alert
06/26/2024Buy Now337.96%JMP Securities
Reni Benjamin
$12 → $12ReiteratesMarket Outperform → Market OutperformGet Alert
06/26/2024Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
$15 → $15ReiteratesBuy → BuyGet Alert
06/04/2024Buy Now337.96%JMP Securities
Reni Benjamin
$12 → $12ReiteratesMarket Outperform → Market OutperformGet Alert
06/03/2024Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
$15 → $15ReiteratesBuy → BuyGet Alert
05/24/2024Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
 → $15ReiteratesBuy → BuyGet Alert
05/06/2024Buy Now337.96%JMP Securities
Reni Benjamin
 → $12ReiteratesMarket Outperform → Market OutperformGet Alert
05/06/2024Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
 → $15ReiteratesBuy → BuyGet Alert
04/03/2024Buy Now337.96%JMP Securities
Reni Benjamin
 → $12Initiates → Market OutperformGet Alert
03/07/2024Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
$15 → $15MaintainsBuyGet Alert
11/15/2023Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
 → $15ReiteratesBuy → BuyGet Alert
10/31/2023Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
 → $15ReiteratesBuy → BuyGet Alert
09/19/2023Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
 → $15ReiteratesBuy → BuyGet Alert
09/15/2023Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
 → $15ReiteratesBuy → BuyGet Alert
08/24/2023Buy Now228.47%Wedbush
Robert Driscoll
 → $9Initiates → OutperformGet Alert
08/10/2023Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
 → $15ReiteratesBuy → BuyGet Alert
05/25/2023Buy Now202.92%EF Hutton
Michael King
 → $8.3Assumes → BuyGet Alert
05/12/2023Buy Now264.96%B of A Securities
Jason Zemansky
$9 → $10MaintainsBuyGet Alert
05/11/2023Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
 → $15ReiteratesBuy → BuyGet Alert
03/24/2023Buy Now202.92%EF Hutton
Michael King
 → $8.3Reiterates → BuyGet Alert
03/23/2023Buy Now228.47%B of A Securities
Jason Zemansky
 → $9ReiteratesBuy → BuyGet Alert
03/23/2023Buy Now447.45%HC Wainwright & Co.
Andres Maldonado
$20 → $15Reiterates → BuyGet Alert
02/27/2023Buy Now202.92%EF Hutton
Michael King
 → $8.3Reiterates → BuyGet Alert
02/17/2023Buy Now202.92%EF Hutton
Michael King
 → $8.3Reiterates → BuyGet Alert
01/30/2023Buy Now191.97%B of A Securities
Jason Zemansky
$9 → $8MaintainsBuyGet Alert
12/05/2022Buy Now202.92%EF Hutton
Michael King
 → $8.3Initiates → BuyGet Alert
06/02/2022Buy Now629.93%HC Wainwright & Co.
Andres Maldonado
 → $20Assumes → BuyGet Alert
05/11/2022Buy Now520.44%SVB Leerink
Daina Graybosch
$18 → $17MaintainsOutperformGet Alert
11/19/2021Buy Now921.9%SVB Leerink
Daina Graybosch
—MaintainsOutperformGet Alert
09/10/2021Buy Now848.91%B of A Securities——Initiates → BuyGet Alert

FAQ

Q

What is the target price for Werewolf Therapeutics (HOWL) stock?

A

The latest price target for Werewolf Therapeutics (NASDAQ:HOWL) was reported by HC Wainwright & Co. on July 2, 2024. The analyst firm set a price target for $15.00 expecting HOWL to rise to within 12 months (a possible 447.45% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Werewolf Therapeutics (HOWL)?

A

The latest analyst rating for Werewolf Therapeutics (NASDAQ:HOWL) was provided by HC Wainwright & Co., and Werewolf Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Werewolf Therapeutics (HOWL)?

A

There is no last upgrade for Werewolf Therapeutics

Q

When was the last downgrade for Werewolf Therapeutics (HOWL)?

A

There is no last downgrade for Werewolf Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Werewolf Therapeutics (HOWL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Werewolf Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Werewolf Therapeutics was filed on July 2, 2024 so you should expect the next rating to be made available sometime around July 2, 2025.

Q

Is the Analyst Rating Werewolf Therapeutics (HOWL) correct?

A

While ratings are subjective and will change, the latest Werewolf Therapeutics (HOWL) rating was a reiterated with a price target of $15.00 to $15.00. The current price Werewolf Therapeutics (HOWL) is trading at is $2.74, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch